Back

EMPEROR-Pooled: effect of empagliflozin on serious adverse renal outcomes in chronic heart failure – a prospective alpha-protected, Individual patient-level pooled analysis

27 August 2021 (17:42 - 17:50)
Organised by:
Congress Presentation Part of: Hot Line - EMPEROR-Preserved / EMPEROR-Pooled Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Milton Packer

Baylor University Medical Center, Dallas (United States of America)

4 More presentations in this session

Presentation thumbnail
EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
EMPEROR-Preserved - Discussant review.
Professor F. Ruschitzka (Zurich, CH)
Video
Presentation thumbnail
EMPEROR-Pooled - Discussant review.
Professor R. De Boer (Rotterdam, NL)
Slides Video
Presentation thumbnail
EMPEROR-Preserved / EMPEROR-Pooled - Panel discussion.

Access the full session

Session thumbnail
Hot Line - EMPEROR-Preserved / EMPEROR-Pooled
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 17:42 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources